SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)*

BridgeBio Oncology Therapeutics, Inc. (Name of Issuer)

Common Stock (Title of Class of Securities)

(CUSIP Number)

Cormorant Asset Management, LP 200 Clarendon Street, 52nd Floor, Boston, MA, 02116 (857) 702-0377 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/01/2026 (Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Bihua Chen
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 17,878,594.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 17,878,594.00
11	Aggregate amount beneficially owned by each reporting person 17,878,594.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 22.32 %
14	Type of Reporting Person (See Instructions) IN, HC

Comment for Type of Reporting Person:

Note to Row 7, 9 and 11: Excludes 31,675 shares of Common Stock underlying unvested stock options held by Bihua Chen. Includes (i) 4,879,995 shares of Common Stock directly held by Cormorant Private Healthcare Fund III, LP ("Fund III"), (ii) 1,905,046 shares of Common Stock directly held by Cormorant Private Healthcare Fund IV, LP ("Fund IV"), (iii) 5,010,332 shares of Common Stock directly held by Cormorant Private Healthcare Fund V, LP ("Fund V"), and (iv) 6,083,221 shares of Common Stock directly held by Cormorant Global Healthcare Master Fund, LP ("Master Fund"). Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund. Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of the securities held by the each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly. Note to Row 13: Based on an aggregate of 80,107,104 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Cormorant Private Healthcare Fund III, LP
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 4,879,995.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 4,879,995.00
11	Aggregate amount beneficially owned by each reporting person 4,879,995.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 6.09 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

Note to Row 13: Based on an aggregate of 80,107,104 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Cormorant Private Healthcare GP III, LLC
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 4,879,995.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 4,879,995.00
11	Aggregate amount beneficially owned by each reporting person 4,879,995.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 6.09 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

Note to Row 7, 9 and 11: Cormorant Private Healthcare Fund III, LP ("Fund III") is the direct holder of such shares. Cormorant Private Healthcare GP III, LLC serves as the general partner of Fund III. Bihua Chen serves as the managing member Cormorant Private Healthcare GP III, LLC. Note to Row 13: Based on an aggregate of 80,107,104 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Cormorant Private Healthcare Fund V, LP
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 5,010,332.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 5,010,332.00
11	Aggregate amount beneficially owned by each reporting person 5,010,332.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 6.25 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

Note to Row 13: Based on an aggregate of 80,107,104 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Cormorant Private Healthcare GP V, LLC
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 5,010,332.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 5,010,332.00
11	Aggregate amount beneficially owned by each reporting person 5,010,332.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 6.25 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

Note to Row 7, 9 and 11: Cormorant Private Healthcare Fund V, LP ("Fund V") is the direct holder of such shares. Cormorant Private Healthcare GP V, LLC serves as the general partner of Fund V. Bihua Chen serves as the managing member Cormorant Private Healthcare GP V, LLC. Note to Row 13: Based on an aggregate of 80,107,104 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Cormorant Global Healthcare Master Fund, LP
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 6,083,221.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 6,083,221.00
11	Aggregate amount beneficially owned by each reporting person 6,083,221.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 7.59 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

Note to Row 13: Based on an aggregate of 80,107,104 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Cormorant Global Healthcare GP, LLC
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 6,083,221.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 6,083,221.00
11	Aggregate amount beneficially owned by each reporting person 6,083,221.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 7.59 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:

Note to Row 7, 9 and 11: Cormorant Global Healthcare Master Fund, LP ("Master Fund") is the direct holder of such shares. Cormorant Global Healthcare GP, LLC serves as the general partner of Master Fund. Bihua Chen serves as the managing member Cormorant Global Healthcare GP, LLC. Note to Row 13: Based on an aggregate of 80,107,104 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2026.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Helix Holdings II LLC
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0.00 %
14	Type of Reporting Person (See Instructions) OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: BridgeBio Oncology Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 256 E Grand Avenue, Suite 104, South San Fancisco, CALIFORNIA , 94080.
Item 1 Comment: This Amendment No. 3 (the "Amendment") to the Schedule 13D (the "Schedule 13D") originally filed with the United States Securities and Exchange Commission (the "SEC") on February 20, 2024, and amended on March 4, 2025 and August 13, 2025, by Helix Holdings II LLC ("Sponsor"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Global Healthcare Master Fund, LP ("Master Fund"), Cormorant Global Healthcare GP, LLC ("Global GP") and Bihua Chen relating to the common stock, par value $0.0001 per share ("Common Stock"), of BridgeBio Oncology Therapeutics, Inc. ("Issuer"), is being filed to amend the reporting persons and to report the pro rata distribution of shares by Sponsor to its members. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Schedule 13D. The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. Items 4 and 6 to the Schedule 13D are supplementally amended as follows, and Items 2 and 5 to the Schedule 13D are amended and restated as follows.
Item 2.	Identity and Background
(a)	Helix Holdings II LLC ("Sponsor"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Private Healthcare Fund V, LP ("Fund V"), Cormorant Private Healthcare GP V, LLC ("GP V"), Cormorant Global Healthcare Master Fund, LP ("Master Fund"), Cormorant Global Healthcare GP, LLC ("Global GP"), and Bihua Chen (collectively, the "Reporting Persons").
(b)	c/o Cormorant Asset Management, LP, 200 Clarendon Street, 52nd Floor, Boston, MA, 02116.
(c)	The principal occupation of Ms. Chen is Investor. Ms. Chen also serves as a director of the Issuer. The principal business of each of the Sponsor, Fund III, GP III, Fund V, GP V, Master Fund, and Global GP is investing in securities. Cormorant Asset Management, LP serves as the investment manager to the Master Fund. Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund V, and Master Fund. GP III is the general partner of Fund III; GP V is the general partner of Fund V; and Global GP is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Additionally, Ms. Chen is the manager of the Sponsor.
(d)	During the last five years, the Reporting Persons have not been convicted in any criminal proceedings (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, the Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Sponsor is a limited liability company formed under the laws of the Cayman Islands. Fund III is a limited partnership organized under the laws of the State of Delaware. GP III is a limited liability company organized under the laws of the State of Delaware. Fund V is a limited partnership organized under the laws of the State of Delaware. GP V is a limited liability company organized under the laws of the State of Delaware. Master Fund is a limited partnership organized under the laws of the State of Delaware. Global GP is a limited liability company organized under the laws of the State of Delaware. Bihua Chen is citizen of the United States.
Item 4.	Purpose of Transaction
	Item 4 is hereby amended and supplemented as follows: On July 1, 2026, Sponsor distributed 4,528,186 shares of Common Stock, pro rata, to its members for no consideration. Following such transaction, Sponsor holds no shares of Common Stock. As a result of Sponsor's pro rata distribution of shares to its members, (i) Fund III, a member of Sponsor, acquired 2,692,459 shares of Common Stock; (ii) Fund V, a member of Sponsor, acquired 1,704,862 shares of Common Stock; and (iii) Master Fund, a member of Sponsor, acquired 130,865 shares of Common Stock.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 is hereby amended and restated in its entirety as follows: The information set forth in the facing pages of this Schedule 13D with respect to the beneficial ownership of each Reporting Person is incorporated by reference into this Item 5. The aggregate number of shares of Common Stock owned by each Reporting Person is set forth on rows 7 through 11 and row 13 of the cover pages of this Amendment and is incorporated herein by reference. The percentage of the Common Stock held by each Reporting Person is based on an aggregate of 80,107,104 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 12, 2026.
(b)	For each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Amendment and are incorporated herein by reference. With respect to Bihua Chen, excludes 31,675 shares of Common Stock underlying unvested stock options.
(c)	Except for the transactions described in Items 4 and 6 of this Amendment and as described below, the Reporting Persons have not engaged in any transaction during the past 60 days involving the Common Stock of the Issuer. On June 16, 2026, as consideration for her service as a director of the Issuer, Bihua Chen was granted 31,675 stock options to purchase 31,675 shares of Common Stock at an exercise price of $7.73. Such options are unvested and will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to Ms. Chen's continued service to the Issuer through the applicable vesting date.
(d)	To the best knowledge of the Reporting Persons, no one other than the Reporting Persons, or the affiliates of the Reporting Persons, is known to have the right to receive, or the power to direct the receipt of, dividends from, or proceeds from the sale of, the Common Stock reported herein as beneficially owned by the Reporting Persons.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 is hereby amended and supplemented as follows: In connection with the pro rata distribution of shares of Common Stock by Sponsor, each of Fund III, Fund V, and Master Fund entered into a joinder ("Joinder") to that certain lock-up agreement, dated as of August 11, 2025, by and between the Sponsor and the Issuer (the "Lock-Up Agreement"), pursuant to which Fund III, Fund V, and Master Fund agreed to be subject to the transfer restrictions set forth in the Lock-Up Agreement with respect to such distributed shares of Common Stock in the same manner as if such person were an original party thereto and as if such distributed shares were "Lock-Up Shares" thereunder. The foregoing description of the Joinder is subject to and qualified in its entirety by the full text of the Form of Joinder, a copy of which is included as Exhibit 13 and is incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	13. Joinder to Lock-Up Agreement, dated July 1, 2026, by and among BridgeBio Oncology Therapeutics, Inc., Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund V, LP, and Cormorant Global Healthcare Master Fund, LP. 14. Joint Filing Agreement.

SIGNATURE
	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bihua Chen

Signature: /s/ Bihua Chen Name/Title: Bihua Chen, Self Date: 07/06/2026

Cormorant Private Healthcare Fund III, LP

Signature: /s/ Bihua Chen Name/Title: Bihua Chen, Managing Member of Cormorant Private Healthcare GP III, LLC, General Partner of Cormorant Private Healthcare Fund III, LP Date: 07/06/2026

Cormorant Private Healthcare GP III, LLC

Signature: /s/ Bihua Chen Name/Title: Bihua Chen, Managing Member Date: 07/06/2026

Cormorant Private Healthcare Fund V, LP

Signature: /s/ Bihua Chen Name/Title: Bihua Chen, Managing Member of Cormorant Private Healthcare GP V, LLC, General Partner of Cormorant Private Healthcare Fund V, LP Date: 07/06/2026

Cormorant Private Healthcare GP V, LLC

Signature: /s/ Bihua Chen Name/Title: Bihua Chen, Managing Member Date: 07/06/2026

Cormorant Global Healthcare Master Fund, LP

Signature: /s/ Bihua Chen Name/Title: Bihua Chen, Managing Member of Cormorant Global Healthcare GP, LLC, General Partner of Cormorant Global Healthcare Master Fund, LP Date: 07/06/2026

Cormorant Global Healthcare GP, LLC

Signature: /s/ Bihua Chen Name/Title: Bihua Chen, Managing Member Date: 07/06/2026

Helix Holdings II LLC

Signature: /s/ Bihua Chen Name/Title: Bihua Chen, Managing Member Date: 07/06/2026

Exhibit 13

JOINDER TO LOCK-UP AGREEMENT

July 1, 2026

Reference is made to the Lock-Up Agreement, dated as of August 11, 2025, by and among BridgeBio Oncology Therapeutics, Inc., a Delaware corporation (the “Company”) (formerly known as Helix Acquisition Corp. II, a Cayman Islands exempted company, prior to its domestication as a Delaware corporation), Helix Holdings II LLC, a Cayman Islands limited liability company (the “Sponsor”), and the other Holders (as defined therein) from time to time party thereto (as may be amended from time to time, the “Lock-Up Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Lock-Up Agreement.

Section 3 of the Lock-Up Agreement provides that the transfer restrictions set forth in Section 1 of the Lock-Up Agreement do not apply to a Transfer to, among other persons, any members or partners of the Holder or their affiliates, provided that the transferee(s) of such Transfer enter into a written agreement, in substantially the form of this Agreement, agreeing to be bound by these Transfer restrictions.

On or about the date hereof, the Sponsor distributed to its members in accordance with the terms of its organizational documents, all of the Lock-Up Shares held by the Sponsor, in the amounts as set forth on Annex A hereto (such shares, the “Distributed Lock-up Shares”), and in connection therewith, such members agreed to enter into this joinder to the Lock-Up Agreement.

By executing this joinder, each of the undersigned hereby agrees that, as of the date first set forth above, the undersigned shall become a party to the Lock-Up Agreement and shall be bound by, and shall be subject to the transfer restrictions set forth in the Lock-Up Agreement with respect to the Distributed Lock-up Shares, in the same manner as if such person was an original signatory to the Lock-Up Agreement and as if the Distributed Lock-up Shares were “Lock-up Shares” thereunder.

Sections 7 through 9 of the Lock-Up Agreement shall apply to this joinder mutatis mutandis. This joinder may be executed in multiple counterparts, including by means of facsimile or electronic signature, each of which shall be deemed an original, but all of which together shall constitute the same instrument.

[Remainder of Page Intentionally Left Blank.]

IN WITNESS WHEREOF, the undersigned have duly executed this Joinder as of the date first set forth above.

Annex A

Distributed Lock-up Shares

Exhibit 14

JOINT FILING AGREEMENT

Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with respect to securities of BridgeBio Oncology Therapeutics, Inc., a Delaware corporation, and further agree to the filing, furnishing, and/or incorporation by reference of this joint filing agreement (this “Agreement”) as an exhibit thereto. Each of them is responsible for the timely filing of such filings and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party. This Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.

This agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the 6th day of July, 2026.